AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c
AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to conventional therapies in the phase three TH3RESA study presented to the 2013 European Cancer Congress.
Outcome data were announced from 602 women — selected for study because they had disease progression despite treatment with a taxane and at least two HER2-directed therapies (including trastuzumab and lapatinib) — who were randomised to treatment with either: a regimen of their physicians choice or T-DM1 — the drug combining trastuzumab with emtansine.
Professor Hans Wildiers MD, PhD from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, described the combination drug as a ‘silver bullet’ — having a cancer-seeking arm linked to a cell killing molecule. He said the data reaffirm the potential of T-DM1 as a treatment for HER2-positive metastatic breast cancer — demonstrating that the drug has the potential to be a new treatment paradigm for this group of patients who currently have few options.
Tags
Related Episodes
Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial
Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard
Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+
PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer
SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos